Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.68 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | AGXT | P21549 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18745423 | 0.90 | MAOB (0.57) | MAOBMRGPRX4FFAR1IDO1AGXT | |
| SCHEMBL16564407 | 0.88 | MAOB (0.68) | MAOBFFAR1IDO1AGXTTAAR1 | |
| SCHEMBL14547318 | 0.87 | MAOB (0.81) | MAOBMRGPRX4IDO1AGXTTP53 | |
| SCHEMBL15472287 | 0.85 | MRGPRX4 (0.63) | MAOBMRGPRX4FFAR1BCHE | |
| SCHEMBL14854755 | 0.84 | MAOB (0.77) | MAOBMRGPRX4FFAR1IDO1AGXT | |
| SCHEMBL13263642 | 0.83 | MAOB (0.79) | MAOBMRGPRX4IDO1AGXTTP53 | |
| SCHEMBL26581162 | 0.83 | MRGPRX4 (0.68) | MAOBMRGPRX4FFAR1RAB9A | |
| SCHEMBL21234325 | 0.83 | MAOB (0.67) | MAOBMRGPRX4FFAR1 | |
| SCHEMBL171916 | 0.82 | MAOB (0.73) | MAOBMRGPRX4FFAR1IDO1AGXT | |
| SCHEMBL10727095 | 0.82 | RXRA (0.64) | MAOBFFAR1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228463-A1 | SODIUM CHANNEL INHIBITORS AND METHODS OF DESIGNING SAME | CACNA1I, CACNA1B, CACNA1C | MAOB 943/4885MRGPRX4 871/4885FFAR1 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.